Monte Rosa Therapeutics' CMO Sells 6,000 Shares
Filip Janku, Chief Medical Officer at Monte Rosa Therapeutics, sold 6,000 shares on June 29.
Key Points
- Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, sold 6,000 shares on June 29, 2026.
- Monte Rosa Therapeutics, trading on NasdaqGS under GLUE, has a market cap of about $2.04 billion.
- Analysts maintain a positive outlook, with Guggenheim and JP Morgan both rating the stock as a 'buy'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Filip Janku, Chief Medical Officer at Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE), sold 6,000 shares of the company on June 29, 2026. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
On June 29, 2026, Filip Janku, Monte Rosa's Chief Medical Officer, sold 6,000 shares at an average price of $22.95. This sale was not conducted under a Rule 10b5-1 trading plan. On the same day, Janku also purchased 6,000 shares at $7.56. Additionally, Anthony Manning sold 10,000 shares at $23.11 and bought 10,000 shares at $4.16.
Monte Rosa Therapeutics, Inc. Stock Up 73.6%
Shares of Monte Rosa Therapeutics (NasdaqGS: GLUE) traded near $24.20 on Wednesday. The company, which operates in the biotechnology sector, has a market cap of approximately $2.04 billion. It has a forward P/E ratio of -13.34, indicating it isn't currently profitable. The stock's 52-week range spans from $4.12 to $25.77, with a 50-day moving average of $19.09 and a 200-day moving average of $16.34. Monte Rosa's beta is 1.60, reflecting higher volatility compared to the market.
$GLUE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 30, 2026, Guggenheim maintained its 'buy' rating on Monte Rosa Therapeutics with a price target of $35. Previously, on May 11, 2026, JP Morgan also maintained a 'buy' rating, setting a target of $31. The consensus among analysts is positive, with a mean price target of $32.33 based on six analyst opinions.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., headquartered in Boston, Massachusetts, is a biotechnology company specializing in the development of small molecule precision medicines. These medicines aim to degrade specific proteins within the body to treat various diseases, including MYC-driven tumors and autoimmune disorders. The company, led by CEO Dr. Markus Warmuth, employs 187 people and collaborates with major firms like F. Hoffmann-La Roche and Novartis.
Bottom Line
Monte Rosa Therapeutics is closely watched by investors due to its innovative approach in biotechnology and strategic partnerships. The recent insider sale by Filip Janku is noteworthy, but such transactions can occur for many reasons. Analysts remain optimistic, maintaining 'buy' ratings and setting targets above current trading levels. As always, it's important to remember that insider trades and analyst ratings are just pieces of a larger investment puzzle.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.